




RealRate

PHARMACEUTICAL 2023

Edesa Biotech Inc
Rank 307 of 471



Edesa Biotech



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Edesa Biotech Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Edesa Biotech Inc compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 50% points. The greatest weakness of Edesa Biotech Inc is the variable Other Net Income, reducing the Economic Capital Ratio by 186% points.

The company's Economic Capital Ratio, given in the ranking table, is 181%, being 63% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	9,092
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,141
Liabilities, Non-Current	0
Other Assets	2,471
Other Compr. Net Income	-8.3
Other Expenses	0.80
Other Liabilities	44
Other Net Income	-17,548
Other Revenues	0
Property and Equipment	13
Research and Development	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	11,576
Liabilities	2,184
Expenses	0.80
Revenues	0
Stockholders Equity	9,391
Net Income	-17,549
Comprehensive Net Income	-17,553
BaseVar	15,659
ECR before Limited Liability	42%
Economic Capital Ratio	181%